Burbank, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Imaging3, Inc. (OTCQB: IGNG), a development stage company targeting disruptive technologies in the medical imaging industry, is pleased to announce the signing of an agreement with Halteres Associates (Emeryville, CA), a leading bioscience consultancy with extensive, long-term, direct operating experience in a broad spectrum of health sciences disciplines, including the development and commercialization of medical devices and diagnostics.
“We are very excited to have the support of Halteres Associates, during this critical push for FDA review and preparation for commercialization. They bring tremendous operating experience and are involved in many potential market sectors of interest to the Company,” said CEO, John Hollister.
The founding and managing partners at Halteres, Mickey Urdea, Ph.D. and Rich Thayer, MBA, will apply their insights, knowledge and network to Imaging3 by providing commercial analysis, regulatory and reimbursement strategy, operational efficiency and financing advice. For more than a decade much of their work has involved development of improved diagnostic techniques worldwide and the utilization of the data derived from these technologies. Their work has been in conjunction with many global healthcare organizations with the potential to collaborate with Imaging3.
Prior to Halteres, Dr. Urdea founded and served as chief executive officer of Tethys Bioscience, a proteomics-based diagnostics company that has been involved in the prevention of type-2 diabetes (assets acquired by HDL), and was chief executive officer of Quantum Dots Corporation (assets acquired by Life Technologies). He successfully raised more than $100MM in order to finance these companies. Additionally, Dr. Urdea is a founder and the chairman of Catalysis Foundation for Health (CFH), a non-profit organization addressing gaps in global healthcare caused by inefficiencies in disease diagnosis and monitoring. Prior to his current activities, Dr. Urdea founded the Nucleic Acid Diagnostics business at Chiron Corporation, where he pioneered viral load assays for the human hepatitis B, hepatitis C and immunodeficiency viruses. Dr. Urdea is an author on over 200 peer-reviewed scientific publications and has more than 125 issued and pending patents. He received his BS in biology and chemistry from Northern Arizona University (Flagstaff, Arizona), his PhD in biochemistry from Washington State University (Pullman, Washington), and had an NIH postdoctoral fellowship at the University of California (San Francisco, California).
In addition to serving as the managing partner of Halteres, Mr. Thayer serves as the chief executive officer of The Catalysis Foundation for Health. With more than 20 years’ experience in Biosciences, Mr. Thayer was previously vice president and head of business development at Roche Molecular Diagnostics, which included responsibility for strategic planning, and was vice president, head of their $260MM Global Blood Screening Business Unit. Prior to joining Roche, he co-founded and served as chief financial officer and a member of the board of a medical diagnostics company called Praxsys Biosystems. Mr. Thayer started his career at Chiron in the DNA sequencing laboratory where he was a member of the hepatitis C virus discovery team. He has an MBA from the Haas School of Business, University of California (Berkeley, California) and a BS in biochemistry from the University of California (Davis, California).
“We see so many potential transformational applications for the Imaging3 Dominion platform in the US and in many other markets worldwide. We look forward to helping the company develop a cost effective and scalable path to broad commercialization,” said Mickey.
About Imaging3 Inc.
Imaging3, Inc., founded in 1993, has developed a patented medical imaging technology, called the Dominion SmartScan™, that will produce 3D x-ray images, virtually in real time. The SmartScan technology has the potential to allow healthcare professionals to perform diagnostic and therapeutic procedures more quickly and accurately, resulting in higher throughput for the clinicians and fewer safety risks for the patient. In addition, Imaging3’s technology exposes patients to significantly less harmful radiation than current imaging technologies such as CT scans, which the company believes will allow scans to be used in many settings where there are concerns about radiation exposure. The technology also allows for greater portability, easier installation, and a significantly reduced cost burden for the healthcare system overall. Imaging3 is planning to submit a 510K application to the FDA during 2018 in order to gain marketing authorization for the SmartScan technology.
Visit the company’s website at http://www.imaging3.com for detailed information about the company’s technology.
About Halteres Associates, LLC
Founded in 2002, Halteres Associates is a leading bioscience consultancy comprised of more than 200 professionals with extensive direct operating and managerial experience in a broad spectrum of areas of expertise, including research, development, manufacturing, regulation and commercialization of diagnostics, medical devices, therapeutics, research reagents, bioscience tools, and information and communications technologies (ICT). Halteres’ experiences extend from programs targeting High Income Countries to the design and implementation of specific, sustainable solutions in global health for Low and Middle Income Countries.
For more information on Halteres’ people, capabilities and clients, please visit the company’s web site at www.halteresassociates.com.
Safe Harbor Statement
Imaging3 cautions you that any statement included in this press release that is not a description of historical facts is a forward-looking statement. Many of these forward-looking statements contain the words "anticipate," "believe," "estimate," "may" "intend," "expect" and similar expressions. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the company and are subject to a number of risks and uncertainties inherent in the Imaging3’s business, including, without limitation: the company may not ever obtain FDA approval for any of its devices; the company may not be able to secure the funds necessary to support its product development plans; and the company may not ever achieve the market success to sustain a profitable business. In addition, there are risks and uncertainties related to economic recession or terrorist actions, competition from much larger imaging companies, technological obsolescence, unexpected costs and delays, potential product liability claims, and many other factors. More detailed information about Imaging3 and the risk factors that may affect the realization of forward-looking statements is set forth in the company’s filings with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q. Such documents may be read free of charge on the SEC’s website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Imaging3 undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.